Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 31, 2022 - Issue 10
Submit an article Journal homepage
256
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects

Siyi Wanga XiangYa School of Pharmaceutical Sciences, Central South University, Changsha, China;b Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, ChinaView further author information
,
Xiaoyan Yangb Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, ChinaView further author information
,
Jie Huangb Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, ChinaView further author information
,
Shuang Yangb Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, ChinaView further author information
,
Qian Wub Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, ChinaView further author information
,
Honghui Chenb Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, ChinaView further author information
,
Shuting Wub Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, ChinaView further author information
,
Changlin Douc Research and Development Centre, Shandong Boan Biotechnology Co., Ltd, Yantai, People’s Republic of ChinaView further author information
,
Guoping Yanga XiangYa School of Pharmaceutical Sciences, Central South University, Changsha, China;b Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, China;d Department of Pharmacy, the Third Xiangya Hospital, Central South University, Changsha, China;e Research Center of Drug Clinical Evaluation, Central South University, Changsha, China;f National-Local Joint Engineering Laboratory of Drug Clinical Evaluation Technology, Changsha, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5930-586XView further author information
ORCID Icon &
Yuxia Xiangb Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1133-1142 | Received 01 Aug 2022, Accepted 30 Aug 2022, Published online: 07 Sep 2022

References

  • Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis [Consensus development conference; Review]. Am J Med. 1993;94(6):646–650.
  • Tanaka S, Nakamura K, Takahasi N, et al. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system [Review]. Immunol Rev. 2005 Dec;208:30–49.
  • Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation [Review]. Nature. 2003 May;423(6937):337–342.
  • Deeks ED. Denosumab: a review in postmenopausal osteoporosis [Review]. Drugs Aging. 2018 Feb;35(2):163–173.
  • Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases [Review]. J Clin Densitom. 2008 Apr-Jun;11(2):325–338.
  • Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone [Article]. Clin Cancer Res. 2012 Aug;18(16):4415–4424.
  • Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Article]. N Engl J Med. 2009 Aug;361(8):756–765.
  • Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension [Article]. J Bone Miner Res. 2012 Mar;27(3):694–701.
  • Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension [Article]. J Clin Endocrinol Metab. 2013 Nov;98(11):4483–4492.
  • Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT) [Article]. J Clin Endocrinol Metab. 2014 Jul;99(7):2599–2607.
  • Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. Article. 2017 Jul;5(7):513–523.
  • Niu SP, Chen M, Yan DQ, et al. A randomized controlled dose-escalation study of ly06006, a recombinant humanized monoclonal antibody to RANKL, in Chinese healthy adults [Article]. Front Pharmacol. 2022 Jun;13:11.
  • Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update [Article]. Endocr Pract. 2020 May;26:1–46.
  • Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab [Review]. Nat Rev Drug Discov. 2012 May;11(5):401–+.
  • Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [Article]. J Bone Miner Res. 2004 Jul;19(7):1059–1066.
  • Chen Q, Hu CY, Liu YM, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: a randomized, single-blind, placebo-controlled study [Article]. PLoS One. 2018 Jun;13(6):13.
  • Chen HJ, Chen WL, Yuan F, et al. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of CMAB807, a new denosumab biosimilar, in healthy Chinese subjects [Article]. Front Pharmacol. 2022;13:10.
  • Amgen. Amgen PROLIA (denosumab) prescribing information. [cited 2022 Jul]. Available from: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/prolia/prolia_pi.pdf
  • Evenepoel P, D’Haese P, Brandenburg V. Romosozumab in postmenopausal women with osteopenia [Letter]. N Engl J Med. 2014 Apr;370(17):1664.
  • Dempster DW, Lambing CL, Kostenuik PJ, et al. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data [Review]. Clin Ther. 2012 Mar;34(3):521–536.
  • Li E, Subramanian J, Anderson S, et al. Development of biosimilars in an era of oncologic drug shortages [Review]. Drug Des Dev Ther. 2015;9:9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.